Clinical Trials

4 trials
RecentStart dateEnrollment
Lip Neoplasms × Thoracic × Clear all
NCT02012699 2026-05-05

iCaRe2

University of Nebraska

Recruiting
999,999 enrolled
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Anus Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Duodenal Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Hypopharyngeal Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Lip Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Mouth Neoplasms, Multiple Myeloma, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Paranasal Sinus Neoplasms, Paraproteinemias, Penile Neoplasms, Peritoneal Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Sarcoma, Skin Neoplasms, Stomach Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Central Nervous System Neoplasms, Thyroid Nodule, Endometrial Neoplasms, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT04985357 2024-11-25

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Travera Inc

Withdrawn
BreastEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Anus Neoplasms, Appendiceal Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lip Neoplasms, Lung Neoplasms, Mesothelioma, Mouth Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Paranasal Sinus Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Ductal, Small Cell Lung Carcinoma

NCT03602079 2023-08-03

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Klus Pharma Inc.

Phase 1/2 Completed
49 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Liver Neoplasms, Lung Neoplasms, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Stomach Neoplasms, Tongue Neoplasms, Tonsillar Neoplasms, Urologic Neoplasms, Carcinoma, Mucoepidermoid, Cholangiocarcinoma, Rare Diseases